Wholesale of pharmaceutical and medical goods
CAEDO ONCOLOGY AS
Revenue 2024
NOK 0
Operating profit
NOK −3.7m
Equity
NOK 28.6m
Incorporated
2020
Share capital
NOK 165,000
Roles
Daglig lederKjetil Hestdal
Regnskapsfører
Revisor
Styrets lederErlend Petter Skagseth
StyremedlemOle Jesper Dahlberg
StyremedlemJens-Otto Forbergskog
Auditor
Audit firm
UNIC REVISJON AS
UNIC REVISJON AS har 14 registrerte statsautoriserte revisorer.
The Brønnøysund registers name the audit firm, not which individual auditor signs the accounts.
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| SARSIA SEED FOND II AS | 39.8% | 65769.000000 | 2025 |
| SATURN INVEST AS | 21.4% | 35281.000000 | 2025 |
| R OG L AS | 12.0% | 19848.000000 | 2025 |
| K OG K AS | 10.5% | 17408.000000 | 2025 |
| JAC MOE AS | 4.5% | 7440.000000 | 2025 |
| ERM INVEST AS | 3.5% | 5721.000000 | 2025 |
| STENSHAGEN INVEST AS | 3.3% | 5526.000000 | 2025 |
| FARVATN VENTURE AS | 1.7% | 2764.000000 | 2025 |
| METTE RAGNHILD KLØVSTAD OLAFSEN | 1.3% | 2100.000000 | 2025 |
| AAMESO AS | 1.1% | 1823.000000 | 2025 |
| INITIA AS | 0.5% | 906.000000 | 2025 |
| TORBJØRN LEIV ØYE | 0.2% | 277.000000 | 2025 |
| THOMAS MEUM ANDERSEN | 0.2% | 250.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.